Antiepileptic Drug Augmentation for Treatment-Resistant Depression
J Clin Psychiatry 1997;58:361-362 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Letter to the Editor
Sir: The recent case report by Ketter, Callahan, and Post1 illustrating
a positive therapeutic drug/drug interaction for
treatment-resistant anxious depression is an example of outstanding
psychopharmacologic strategizing. The authors explain
their successful outcome, achieved when nefazodone was
added to alprazolam, with a pharmacokinetic model, hypothesizing
that nefazodone extended the duration of action of alprazolam
through inhibiting its degradation by the cytochrome
P450 3A3/4 system, thereby eliminating “interdose dysphoria.”